A Pilot Study of Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for Upfront Treatment of Aggressive B-Cell Non-Hodgkin Lymphomas

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT07097363

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-25T22:29:04.557452+00:00

Published At

2026-04-23T00:00:00+00:00

Record Updated At

2026-04-23

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["B-Cell Non-Hodgkin Lymphoma", "Burkitt Lymphoma", "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements", "High Grade B-Cell Lymphoma, Not Otherwise Specified", "Primary Mediastinal Large B-Cell Lymphoma", "T-Cell/Histiocyte-Rich Large B-Cell Lymphoma", "Transformed B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma to Diffuse Large B-Ce"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2026-04-23"

protocolSection.identificationModule.nctId

"NCT07097363"

protocolSection.identificationModule.officialTitle

"A Pilot Study of Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for Upfront Treatment of Aggressive B-Cell Non-Hodgkin Lymphomas"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• B-Cell Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
• Burkitt Lymphoma (protocolSection.conditionsModule.conditions)
• Diffuse Large B-Cell Lymphoma, Not Otherwise Specified (protocolSection.conditionsModule.conditions)
• EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified (protocolSection.conditionsModule.conditions)
• High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements (protocolSection.conditionsModule.conditions)
• High Grade B-Cell Lymphoma, Not Otherwise Specified (protocolSection.conditionsModule.conditions)
• Primary Mediastinal Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
• T-Cell/Histiocyte-Rich Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Transformed B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma to Diffuse Large B-Ce (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.